Weight Loss Medication and Type 2 Diabetes: What Patients Need to Understand About GLP-1 Treatment in a Diabetic Context

Reviewed by GPhC Pharmacist at Priory Pharmacy, York

The relationship between obesity and type 2 diabetes is bidirectional and well-established.

• Excess adiposity, particularly visceral adiposity, drives insulin resistance, beta-cell dysfunction, and the metabolic syndrome that characterises type 2 diabetes
• Conversely, type 2 diabetes alters the metabolic environment in ways that make weight loss harder to achieve and, critically, reduce the magnitude of weight loss produced by GLP-1 receptor agonist therapy

Understanding this relationship is important for:

• Patients with type 2 diabetes who are considering weight management medication
• Those who are at risk of developing diabetes and may be hoping to prevent it

How Type 2 Diabetes Affects the Response to GLP-1 Medication

In the STEP 2 trial, adults with type 2 diabetes and obesity treated with semaglutide 2.4 mg achieved a mean weight loss of approximately 9.6% body weight over 68 weeks, compared with 14.9% in the STEP 1 trial conducted in adults without diabetes.

Similarly, in SURMOUNT-2 (tirzepatide in adults with type 2 diabetes and obesity), mean weight loss at the 15 mg dose was approximately 15.7%, compared with 20.9% in SURMOUNT-1 (adults without diabetes).

This attenuated response in people with type 2 diabetes is thought to reflect several mechanisms:

• The underlying beta-cell dysfunction and insulin resistance alter the metabolic response to GLP-1 receptor activation
• Glucose lowering effects of the medication require physiological resources that reduce the net weight loss
• The hormonal environment in established type 2 diabetes is more profoundly disrupted than in obesity alone

This does not mean GLP-1 therapy is ineffective in type 2 diabetes. The weight loss achieved, even if lower on average than in non-diabetic patients, is clinically significant. A 10 percent weight loss in a patient with type 2 diabetes and obesity can:

• Meaningfully improve glycaemic control
• Reduce antidiabetic medication burden
• Improve blood pressure and lipid profiles
• In some patients with early type 2 diabetes, contribute to diabetes remission

GLP-1 Medicines Licensed for Diabetes vs Weight Management: An Important Distinction

Several GLP-1 receptor agonists are licensed in the UK for both type 2 diabetes management (at lower doses) and for weight management (at higher doses). The distinctions are clinically important and affect prescribing pathways:

Semaglutide for diabetes Ozempic (0.5 mg or 1 mg once weekly) is licensed for glycaemic control in type 2 diabetes. It is not the same product or dose as Wegovy (semaglutide 2.4 mg), which is licensed for weight management.

Tirzepatide for diabetes Mounjaro is licensed in the UK for both type 2 diabetes (at doses up to 15 mg) and for weight management in obesity with comorbidities. It is currently available through the NHS in some areas for type 2 diabetes, and privately for weight management.

The licensing status, prescribing pathway, and funding differ between the diabetes and weight management indications.

Patients with type 2 diabetes should discuss with their prescriber whether their current antidiabetic regimen needs to be reviewed when starting GLP-1 therapy for weight management particularly if they are on insulin or sulphonylureas (which carry hypoglycaemia risk when combined with the glucose-lowering effect of GLP-1 therapy).

Weight Loss as a Disease-Modifying Intervention in Type 2 Diabetes

The DiRECT trial demonstrated that an intensive dietary weight management programme produced diabetes remission (HbA1c below 48 mmol/mol without antidiabetic medication) in:

• 46% of participants at one year
• 36% at two years

Remission rates strongly correlated with the amount of weight lost — those achieving the largest weight losses had the highest remission rates.

This was a landmark finding. It established that:

• Type 2 diabetes in its early stages is not inevitably progressive
• Sufficient weight reduction can restore glycaemic function

GLP-1 medicines do not yet have equivalent remission data in the DiRECT sense, partly because most participants remain on medication rather than stopping it to test remission. However, GLP-1 therapy achieves substantial weight loss alongside glycaemic benefit, and its role as a disease-modifying intervention in obesity-related type 2 diabetes is increasingly recognised in UK clinical guidance.

Key Considerations for Patients With Type 2 Diabetes Starting GLP-1 Therapy

• Inform your prescriber of all current antidiabetic medications before starting
• Blood glucose monitoring frequency may need to increase initially
• Dose reduction of insulin or sulphonylureas may be needed to avoid hypoglycaemia
• HbA1c and renal function should be reviewed at appropriate intervals during treatment
• Weight loss targets and expectations should be discussed: the response in type 2 diabetes is real but statistically somewhat lower than in non-diabetic patients

This article is for general information and does not constitute individual clinical advice. To discuss weight management with type 2 diabetes at Priory Pharmacy in York, please book a consultation with our clinical team.